Abstract
Background and Aims: The ESC/EAS 2019 guidelines for the management of dyslipidemia recommend aggressive LDL-C targets in patients with familial hypercholesterolemia (FH). Intensive hypolipidemic treatment with statin and ezetimibe is often insufficient to achieve these targets. For very-high-risk FH patients (that is, with atherosclerotic cardiovascular disease or with another major risk factor) who do not achieve their goal on a maximum tolerated dose of a statin and ezetimibe, the addition of a PCSK9 inhibitor (PCSK9i) is recommended.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
